Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492697 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
A Phase 1 study of Healthy Subjects, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03492697 is a Phase 1 study of Healthy Subjects that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03492697, a Phase 1 study of Healthy Subjects, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.
Conditions Studied
Interventions
- DRUG PF-06882961 Immediate Release Tablet
- DRUG PF-06882961 Controlled Release Tablet (long)
- DRUG PF-06882961 Controlled Release Tablet (short)
- DRUG PF-06882961 Immediate Release Solution
Study Locations (1)
Connecticut
- Pfizer New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2018-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03492697
The ClinicalTrials.gov registry entry for NCT03492697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 4 interventions - of which PF-06882961 Immediate Release Tablet is the first listed.
NCT03492697 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03492697 about?
NCT03492697 is a clinical study titled "A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961". This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjec...
What is the current status of trial NCT03492697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-04-30. Estimated completion is 2018-07-18.
What conditions does trial NCT03492697 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT03492697?
The interventions under investigation include: PF-06882961 Immediate Release Tablet (DRUG), PF-06882961 Controlled Release Tablet (long) (DRUG), PF-06882961 Controlled Release Tablet (short) (DRUG), PF-06882961 Immediate Release Solution (DRUG).
Who is sponsoring clinical trial NCT03492697?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492697 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.